Abstract Details

Title Is the Mental Health Burden of Epilepsy Under-Recognized in Patients Reporting Focal Onset Seizures (FOS)? A Patient-Reported Outcomes Study

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P6 - Poster Session 6 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-001

Objective Examine the mental health burden of epilepsy in patients reporting FOS using a web-enabled survey.

Background There remains a gap in our understanding of the real-world mental health burden of patients with FOS using validated patient-reported outcome measures (PROMs).

Design/Methods Eligible patients were 18 to 80 years, with a diagnosis of FOS for ≥1 year, ≥1 seizure per month, past/present use of >2 antiseizure medications (ASMs), and currently receiving an ASM for >1 month. Mental health data were collected via a questionnaire and validated PROMs for depression and anxiety.

Results 170 patients completed the survey; 66.5% (113/170) reported having >1 seizures a month, and 72.9% (124/170) reported ≥3 non-seizure-related symptoms despite ASM treatment. Mood issues (e.g., depression, anxiety) were the most common non-seizure symptoms, with 76.5% (130/170) reporting symptoms and 53.1% (69/130) indicating them to be highly severe. The mean (SD) Patient Health Questionnaire-9 (PHQ-9) depression severity score for all patients was 11.2 (5.2) out of 27. 63.5% (108/170) had a PHQ-9 score ≥10, suggestive of moderate-to-severe depression, although 52.8% (57/108) had no prior depression diagnosis. In addition, 20.6% reported having suicidal ideation or thoughts of self-harm on >7 days of the past 2 weeks; 4.7% had these thoughts daily. The mean (SD) Generalized Anxiety Disorder-7 score for all patients was 8.9 (4.8) out of 21. 46.5% (79/170) had a score of ≥10, suggestive of moderate-to-severe generalized anxiety, although 40.5% (32/79) reported no prior anxiety diagnosis. In addition, 37.7% reported that their anxiety symptoms made it very, or extremely difficult to work, take care of the home, or socialize.

Conclusions Patients with FOS reported considerable mental health burden in addition to recurring seizure burden. The high rates of self-reported depression and anxiety, in contrast to lower rates of diagnosed depression and anxiety, suggest mental health burden may be under-recognized in patients with FOS.

Authors/Disclosures
Joanne M. Wagner, PhD, PT PRESENTER	Dr. Wagner has received personal compensation for serving as an employee of Xenon Pharmaceuticals, Inc.. Dr. Wagner has stock in Biogen. Dr. Wagner has stock in Xenon Pharmaceuticals, Inc..
Bhagyashree Oak, PhD	Dr. Oak has received personal compensation for serving as an employee of Trinity Life Sciences. An immediate family member of Dr. Oak has received personal compensation for serving as an employee of Intellia Therapeutics. An immediate family member of Dr. Oak has stock in Intellia Therapeutics.
Brittany C. Smith, MPH, MBA	Miss Smith has received personal compensation for serving as an employee of Trinity Life Sciences.
Amod Athavale, PhD	Dr. Athavale has received personal compensation for serving as an employee of Trinity Life Sciences. Dr. Athavale has stock in Trinity Life Sciences.
Jeffrey Skaar, PhD	Dr. Skaar has received personal compensation for serving as an employee of Trinity Life Sciences. Dr. Skaar has received personal compensation for serving as an employee of Novo Nordisk. Dr. Skaar has stock in Trinity Life Sciences. Dr. Skaar has stock in Novo Nordisk.
Alvin Ong, PharmD	Dr. Ong has received personal compensation for serving as an employee of Xenon Pharmaceuticals. Dr. Ong has stock in Xenon Pharmaceuticals.
Cynthia Harden	No disclosure on file

��ɫ��

��ɫ��